

Neil Johnson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2526789/publications.pdf>

Version: 2024-02-01

16
papers

1,277
citations

567281

15
h-index

888059

17
g-index

18
all docs

18
docs citations

18
times ranked

2133
citing authors

#	ARTICLE	IF	CITATIONS
1	ATF3 coordinates serine and nucleotide metabolism to drive cell cycle progression in acute myeloid leukemia. <i>Molecular Cell</i> , 2021, 81, 2752-2764.e6.	9.7	28
2	RNF168-mediated localization of BARD1 recruits the BRCA1-PALB2 complex to DNA damage. <i>Nature Communications</i> , 2021, 12, 5016.	12.8	35
3	BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis. <i>Cancer Research</i> , 2020, 80, 4601-4609.	0.9	30
4	BRCA1 Mutational Complementation Induces Synthetic Viability. <i>Molecular Cell</i> , 2020, 78, 951-959.e6.	9.7	41
5	Ectopic RNF168 expression promotes break-induced replication-like DNA synthesis at stalled replication forks. <i>Nucleic Acids Research</i> , 2020, 48, 4298-4308.	14.5	13
6	RNF168-Mediated Ubiquitin Signaling Inhibits the Viability of <i>BRCA1</i> -Null Cancers. <i>Cancer Research</i> , 2020, 80, 2848-2860.	0.9	21
7	BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation. <i>Molecular Cell</i> , 2019, 73, 1267-1281.e7.	9.7	78
8	BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. <i>Nature Communications</i> , 2019, 10, 5661.	12.8	45
9	Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. <i>Nature Communications</i> , 2018, 9, 3970.	12.8	192
10	BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. <i>Cell Reports</i> , 2018, 24, 3513-3527.e7.	6.4	61
11	The BRCA1- Δ 11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. <i>Cancer Research</i> , 2016, 76, 2778-2790.	0.9	208
12	RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance. <i>Journal of Clinical Investigation</i> , 2016, 126, 3145-3157.	8.2	74
13	Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 17041-17046.	7.1	225
14	Cyclin-dependent kinase 4/6 inhibition in cancer therapy. <i>Cell Cycle</i> , 2012, 11, 3913-3913.	2.6	19
15	Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 1199-1212.	3.4	90
16	Cdk1 Participates in BRCA1-Dependent S Phase Checkpoint Control in Response to DNA Damage. <i>Molecular Cell</i> , 2009, 35, 327-339.	9.7	109